Molecular imaging advances
Kereos, from St Louis, MI, develops targeted therapeutics and molecular imaging agents that detect and attack cancer and cardiovascular disease earlier and more specifically than previously possible.
Kereos, from St Louis, MI, develops targeted therapeutics and molecular imaging agents that detect and attack cancer and cardiovascular disease earlier and more specifically than previously possible.
Molecular imaging negates the need for biopsy needles and endless days of waiting for test results by offering a non-invasive tumour detection technology. But its true advantage is that it can find very small tumours at an early stage, when they can be most easily attacked. At the heart of this type of molecular imaging technology are researchers from Washington University/Barnes-Jewish Hospital, who have spent the last decade developing molecular imaging agents that find tumours as small as the head of a pin (1 mm) in size. This is a significant diagnosis improvement considering most malignant solid tumours are almost the size of a grape by the time they are diagnosed.
Kereos, is currently testing the technology both for imaging and as a means of delivering powerful anticancer therapeutics directly to tumours. CEO Al Beardsley believes its commercialisation may be one of the most powerful factors in preventing deaths from cancer.